Showing 7651-7660 of 8693 results for "".
- AARS Shines Light on Antibiotic Resistance During Rosacea Awareness Monthhttps://practicaldermatology.com/news/aars-shines-light-on-antibiotic-resistance-during-rosacea-awareness-month/2461664/The American Acne and Rosacea Society (AARS) is calling on patients and prescribers to ensure appropriate use of antibiotics to manage rosacea during Rosacea Awareness Month. “It has been well known for many years that dermatologists prescribe more antibiotics per clinician than p
- Almirall to Assess Wellbeing in Psoriasis Studyhttps://practicaldermatology.com/news/almirall-to-assess-wellbeing-in-psoriasis-study/2461658/
- First Patient Dosed in Phase 2 Trial of ADX-629 in ADhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-2-trial-of-adx-629-in-ad/2461650/Aldeyra Therapeutics, Inc.
- Iovance Biotherapeutics Completes Biologics License Application Submission for Lifileucel in Advanced Melanomahttps://practicaldermatology.com/news/iovance-biotherapeutics-completes-biologics-license-application-submission-for-lifileucel-in-advanced-melanoma/2461633/Iovance Biotherapeutics announced it has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced (unresectable or metastatic) melanoma w
- Rosacea Pipeline Update: Tarsus Starts Phase 2A Trial of TP-04 in PPRhttps://practicaldermatology.com/news/rosacea-pipeline-update-tarsus-starts-phase-2a-trial-of-tp-04-in-ppr/2461604/
- Ribon Therapeutics: First Patient Dosed in Phase 1 Study with RBN-3143 of ADhttps://practicaldermatology.com/news/ribon-therapeutics-first-patient-dosed-in-phase-1-study-with-rbn-3143-of-ad/2461599/Ribon Therapeutics dosed the first patient with RBN-3143 in the open-label cohort of patients with moderate-to-severe atopic dermatitis. The study aims to measure the pharmacodynamic activity of RBN-3143 and evaluate the safety and preliminary efficacy of 28 days of administration of RBN-3143 in
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Kintor Pharma’s GT20029 Performs Well in Phase 1 Trial of Acne and Androgenetic Alopeciahttps://practicaldermatology.com/news/kintor-pharmas-gt20029-performs-well-in-phase-i-trial-of-acne-and-androgenetic-alopecia/2461559/Kintor Pharmaceutical Limited’s GT20029 was safe and well tolerated and had good pharmacokinetic characteristics in healthy people and people with androgenetic alopecia (AGA) or acne, according to a phase 1 clinical trial. GT20029 is the first topical PROTAC compound in the world
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Evelo Biosciences’ Atopic Dermatitis Candidate Misses Primary Endpoint in Phase 2 Trialhttps://practicaldermatology.com/news/evelo-biosciences-atopic-dermatitis-candidate-misses-primary-endpoint-in-phase-2-trial/2461540/Data from first three cohorts of Evelo Biosciences’ EDP1815 Phase 2 trial show the atopic dermatitis drug candidate did not meet the primary endpoint, the company announced on Wednesday. Evelo stated that there was an unusually high placebo response rate in the first three cohorts of the st